Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic CancerGlobeNewsWire · Oct 19, 2026
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong BuyZacks Investment Research · Oct 16, 2026
New Strong Buy Stocks for October 16thZacks Investment Research · Oct 16, 2026
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced TherapiesGlobeNewsWire · Sep 22, 2026Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.13 | -$0.09 | Beat |
| May 15, 2026 | -$0.18 | -$0.16 | Beat |
| Mar 18, 2026 | -$0.21 | -$0.10 | Beat |
| Nov 13, 2025 | -$0.36 | -$0.12 | Beat |
| Aug 14, 2025 | -$0.30 | -$0.29 | Beat |
| May 15, 2025 | -$0.66 | -$0.40 | Beat |